On Tuesday, Lineage Cell Therapeutics Inc (AMEX: LCTX) was -5.13% drop from the session before settling in for the closing price of $0.46. A 52-week range for LCTX has been $0.37 – $1.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 120.15% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -4.76%. With a float of $227.36 million, this company’s outstanding shares have now reached $228.36 million.
In an organization with 77 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 94.64%, operating margin of -226.11%, and the pretax margin is -195.62%.
Lineage Cell Therapeutics Inc (LCTX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Lineage Cell Therapeutics Inc stocks. The insider ownership of Lineage Cell Therapeutics Inc is 0.44%, while institutional ownership is 52.01%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -4.76% per share during the next fiscal year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
You can see what Lineage Cell Therapeutics Inc (LCTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.10, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.73 million. That was inferior than the volume of 1.6 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 41.09%. Additionally, its Average True Range was 0.04.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 18.17%, which indicates a significant decrease from 30.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.28% in the past 14 days, which was lower than the 85.95% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.4841, while its 200-day Moving Average is $0.6998. However, in the short run, Lineage Cell Therapeutics Inc’s stock first resistance to watch stands at $0.4649. Second resistance stands at $0.4947. The third major resistance level sits at $0.5109. If the price goes on to break the first support level at $0.4189, it is likely to go to the next support level at $0.4027. Assuming the price breaks the second support level, the third support level stands at $0.3729.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
There are 228,356K outstanding shares of the company, which has a market capitalization of 99.33 million. As of now, sales total 9,500 K while income totals -18,610 K. Its latest quarter income was 2,870 K while its last quarter net income were -3,270 K.
